London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Started: NoOneKnows, 14 Jun 2024 07:59
Last post: LTbeliever, 14 Jun 2024 11:09
IMO, these pathogen detectors will not be ready before 2025; however, MSYS may have a 1st mover advantage (BTW, I also hold MSYS) and is working on other detectors too (toxicity, PFAS etc); the potential is big (all water suppliers in EU, USA and Mid-East) so APTA will benefit handsomely if successful, but not in the near future; the plus is that the Aptamers would need to be replenished constantly.
Yes, this is an interesting addition.
Given the very prolonged issues facing SW Water 💦 trying to determine the source of the Cryptosporidium outbreak in the Torquay/Brixham district and the tens of thousands infected & affected.
Still, after more than a month tens of thousands of households are on bottled water.
However, I patiently await the update on a material license fee opportunity.
According to the previous RNS there should be alot more positive news coming
More positive news.
Started: originalharrystamper, 13 Jun 2024 14:35
Last post: LTbeliever, 13 Jun 2024 16:43
Bear in mind this is about 2 years away (as mentioned by ATolley in a presentation); more urgent is to close the Y/E24 with another 2-3 RNSs, putting all the cash flow worries to bed, the soonest (by 1st week of July).
No probs LT - could potentially revolutionise the deodorant market. Not to be confused with the antiperspirant which blocks sweat pores, it seems they are looking at how to inhibit the enzymes involved in body odour formation - Bacterial C-S lyase represents one of the key enzymes involved in human body odour formation.. The aim of this study I referenced in the earlier post was to identify compounds inhibiting the C-S lyase activity of a Staphylococcus sp. isolate from the human skin. I’m not saying there’s a connection between the patent and this study, it a just a reference I found which helped me better understand what staphylococcal c-s lyase is and how it could be linked to the cosmetics market and potentially Unilever.
Very interesting, deodorants by UNILEVER, based on APTA's patent.
Thanks OHS
I scrolled back to posts around the 8th April but couldn't see a posted link to the patent they RNS'd so I've added it below:
Aptamers against staphylococcal c-s lyase
https://www.ipo.gov.uk/p-ipsum/Case/ApplicationNumber/GB2404469.5
I also researched 'staphylococcal c-s lyase' and found it to be linked with body odour:
https://pubmed.ncbi.nlm.nih.gov/23941521/
"The C-S lyase activity of bacteria in the human armpit releases highly malodorous, volatile sulfur compounds from nonvolatile precursor molecules. Such compounds significantly contribute to human body odour. Hence, C-S lyase represents an attractive target for anti-body-odour cosmetic products."
OHS
Started: originalharrystamper, 13 Jun 2024 11:19
Last post: originalharrystamper, 13 Jun 2024 11:19
The following link is a really detailed and interesting read of "The Application of Aptamer and Research Progress in Liver Disease":
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11087326/
Last post: LTbeliever, 7 Jun 2024 19:50
They specifically say Top 5, Top 10, Top 15 but no idea why; could be the NOMAD requiring it (mkt practice?) or, the Clients themselves (self-defining?).
Since the Co wants the RNS to have maximum impact (positive spin), I assume the Co itself wants to show the Mkt how "big" the client is; and that's the most permissible way i.e. to satisfy both the NOMAD and the client demanding confidentiality; had the Co defined the ref. year (eg Top 5 in 2023) then, what's the point of vagueness? IMO
Hi LT, thanks for the links. I guess we’ll find out when the name is finally released in an RNS update or other media outlet. For now, I will look upon this from a positive angle and assume that whilst I agree with the statement in your first link - that references ‘historical partnerships’ with 15 of the 20 top Pharmas from 2020, this doesn’t necessarily mean that they were referencing the same when stated top 15 in the April RNS. This could well be the current top 15 as it doesn’t state 2020 (nor does it state 2023/24 either). I’ll ask you this though; why did they say ‘top 15’ and not top 10? Top 5, top 8 etc….. why not just say top 20 and keep it vague?
FWIW, link below confirms that the Co refers to 2020 revenues (for Top 20 Pharma partners) - see footnote, page 6
https://aptamergroup.com/wp-content/uploads/2024/03/Aptamer-Group-Interim-Pres-Mar-2024.pdf
This link is the 20 Top Pharma Cos, in 2020; Boehringer Ingleheim is #16, so quite close!
http://www.stacommunications.com/journals/cpm/2021/Volume_34_Number_1/Wall_Street_View.pdf
Harry, make of this what you will...
https://x.com/Greeninthewoods/status/1795836074545361194
The original drug from 2020 was imatinib which is made by Novartis,
Dr Tolley makes it quite clear that while they have something that can deliver imatinib, it is the not the drug in question.
So, if I am correct in thinking - Boehringer Ingleheim, whilst trialling Zealand Pharma's Survodutide (under development for the treatment of non-alcoholic steatohepatitis (NASH), liver fibrosis, type 2 diabetes and obesity) they found during sub-analysis that up to 64.5% of adults with fibrosis stages F2 and F3 (moderate to advanced scarring) achieved an improvement in fibrosis without worsening of MASH (Metabolic dysfunction-associated steatohepatitis - inflammation of the liver caused by excess fat cells in it). Could Aptamer Group's Optimer now be used to specifically target fibrosis??, as mentioned in the April RNS "it's Optimer binder against cells associated with fibrotic liver disease, developed for targeted delivery of therapeutic payloads to fibrotic liver disease, has been shipped to a top 15 pharmaceutical company for evaluation in their own therapeutic applications".
Started: Porky9, 1 Jun 2024 12:58
Last post: LTbeliever, 6 Jun 2024 12:57
I'm quite confident that you will make a huge gain, and the pain will be very short term; just 3 weeks to FY24 end, Mgt has sounded very bullish in the past few weeks so I reckon there are a few more super RNSs on the way - just IMO of course.
Downside limited at these levels, upside substantial once this "placing" palaver is out of the way.
The stand out factor for me is the quality and size of the companies entering into relationships with Apta on a wide range of possible developments. Any one of these could lead to significant revenue which in context is not a lot of money. If expenses are running at £300k per month or £3.6m per annum that could be reached within 12 months IF progress is achieved.
Anyway bought another 500k shares shown on LSE as a sell.
@Mozak,
You can be as bullish as you like but realistically, the contractual side of these sort of deals alone can take 8-12 weeks and that's after DD phases to establish if Heads of Terms can be agreed. I genuinely cant see how they can get terms and the cash actually in the bank before the cash runway is out.
That's not a negative BTW, i consider it a commercial reality, its just business, it will take longer than the current remaining runway, that's how i see it.
I disagree with you.
Let’s see what this license fee opportunity is first, then we can discuss whether a raise is necessary, and if so, how much.
Personally, I think this stock could come good long term if the right deals ultimately get struck however that will take significantly more time, not to mention there is a massive lag between a secured win and payments actually hitting the business. That is clear as day from the H1 results report.
I also find it both shocking and concerning how much business they have lost, revenue in H1 as I have previously posted was less than my local sandwich bar, how any business can tank from doing close to £6m of revenue to next to FA is a concern whilst still burning eye watering amounts of cash each month is beyond me, although I don’t doubt measures are in play to try and turn things around.
However, Short term I can see the SP tanking significantly especially when the raise gets sorted, and it will do, because they did not hit the required revenues they forecast. I think they have done well to put out spin, to sex up interest and pump the SP from .5 back to .8 but talk is cheap and it doesn’t pay the bills, that's the reality.
They are less than 4 weeks now from the Year end and from a cash runway perspective must be running on fumes so the raise imo is bolted on and my call is .4 or .5 on a good day. We will know soon enough.
Will one more raise be enough? Hopefully, if they can secure it and they gone on and shore up the business wins after but, as I say, the top line order potential value doesn't convert quickly to bottom line cash in the business, it would not surprise me if the income for H2 proves to be as dire as H1 due to the delays, so I think it essential that next raise is the last one with a clear route to the break even delivered.
People will only buy into Jam tomorrow for so long, they are great at the talking the talk, they now need to walk the walk...
I'm 50/50 on this one, short term SP is going south IMO especially after the placing dilution, longer term could be interesting if they start to deliver.
Good luck
Started: Fredd1eboy, 3 Jun 2024 10:34
Last post: Fredd1eboy, 3 Jun 2024 10:34
Started: LTbeliever, 1 Jun 2024 14:35
Last post: viera, 1 Jun 2024 19:54
I’m still very bullish here
Just lightened the load as bought 950k insg at 12p.
Adam is incredible and imho will make a killing here .
Porky, us dreamers 'll take our chances. You have a few more weeks for your flying lessons :)
@LTBeliever
Brilliant - if you believe that you believe anything - good to be a dreamer. If you think that’s going to be a reality I will start flying...
Seen it all before and worn the TShirt
Cash sufficient to Aug24, as at end of Jan.24, plus cash from all the deals and pending business since then (which is over 2mln for signed deals, plus 3+mln advanced stage, plus unknown amount of under the radar contracts/recurring business); this -assuming a NPM of 50% - will add another 2+mln cash for calendar 2024 i.e. extra 7 months, which takes us to Spring 2025 (ignoring 400k+ tax refund in Q1 2025). By then, obviously, more deals will be announced.
Started: LTbeliever, 31 May 2024 16:53
Last post: Porky9, 1 Jun 2024 12:48
You should focus on this stock and its performance to date not the individuals frankly.
Time that PI use these boards to discuss pros and cons of an investment and do their own research not spend time speculating on other individuals investing strategy.
Look at the RNS -- He sold from 4% down to 2.5; this is around 7mln shares.
Took profit? His average is around 1.05p?? He’s selling at a loss?
Looks like our boy, Slater, took some profits?
Started: Karlvonwise, 23 May 2024 08:31
Last post: LTbeliever, 30 May 2024 13:01
A bit more patience only is needed; About 20 trading days left to the Y/E 2024, I am sure we will get another 3-4 RNSs by 30 June.
3v1 on L2.
Maybe a sell order still holding us back as a few decent buys is rapidly followed by a chunky sell.
Pretty sure our seller must be done soon, this has been held back for quite a while.
It may not just be Unilever.
We've been promted a few times about the Liver related work they've been doing.
Have a look at this from 2020:
https://aptamergroup.com/aptamer-group-making-progress-in-2020/
Look at the section they refer to "Small molecule aptamers in press!"
They are discussing the use of their aptamers with imatinib, a liver chemo drug manufactured by Novartis.
Just imagine the momentum if they get a deal with Unilever.
Seems as though this has now churned through, sellers have disappeared & stock has become very tight.
Just await our next update that AT has suggested he’s ‘excited’ to announce ‘in due course’.
A material licence fee opportunity.
Will it be a pivotal moment?
Started: Superda, 22 May 2024 07:31
Last post: Superda, 23 May 2024 08:28
When CTO confirms that there won’t be any placing in these levels, I think we will have to trust him on that ! They wouldn’t want to break investor’s trust at these crucial times !
I think Porky could be right despite today's RNS. The sort of money we see coming in from these contracts is not going to stop the need for a raise an it may be prudent for the company to go to market to alleviate any funding concerns.
It’s definitely rerate time in my opinion. No risk of placing according to the CTO and revenue flowing from contracts with top companies!
GLA
Strangely enough, I watched a programme last night on a Company in the U.S. that scammed billions from investors using their blood sample analysis to detect diseases. It was all a con,but shows that these types of blood test are in massive demand. At least this one is real with other test to come. Havn`t a clue what price APTA could reach so just going to hold.
Https://timsergroup.com/labinvestigacionen.html
Looks like they are in Mexico? Really came out of nowhere, it just shows how many "surprises" like this might be coming our way soon. Remember, Arron promised more announcements by June end.
Started: bobbust, 23 May 2024 08:00
Last post: Superda, 23 May 2024 08:19
@iceman - I became a LTH recently seeing the huge potential of this company. BOD have done a great job here. Well settled for a huge rerate. Remember 52 week’s high was 30.50.
GLA
Excellent work!
Been buying these last few weeks!
This is who the BOD should be updating shareholders. You can tell these people are working hard. Results will come!
GREAT WORK BOD!
YOU HAVE OWN ANOTHER LT HOLDER HERE!
LFG!!!
Contracts confirmed but sales pipeline increasing.
So it looks like they are adding more than converting which is very good.
More contracts to be confirmed
A good update on the progress of our sales pipeline, demonstrating the momentum that is building.
For me, the standout comment is this:
‘An important part of our strategy includes horizon scanning for material licence fee opportunities, and I am excited to share further information on this in due course.’
Material licence opportunities.
That’s what we want here, and there are numerous opportunities.
Started: Wisheyedbortum, 23 May 2024 07:43
Last post: Wisheyedbortum, 23 May 2024 07:43
I haven’t Researched this company too much, but at this price it seemed like a reasonable punt. It’s following similar lines to Avacta.
Started: bobbust, 22 May 2024 10:20
Last post: tintin35, 23 May 2024 07:35
Maybe wait a couple of hours next tine......
Porky, we'd call u the "God of Aptamer", u always seem to post prior to a fresh RNS!
Look this is another one where the Directors previously drew the best part of a million quid a year out of it for lavish lifestyles. They only started cutting cost when they had no option, the last raise was subject to that. Old habits die hard, we await to see the full effect of the cost cuts.
Meanwhile, the proof is in the delivery, the H1 confirmed figures were appalling, lets call a spade a spade. Talk of BIG orders worth millions yet they confirmed further declining revenues and Delivered revenue less than my local cafe. No idea why a projected massive order value only results in a paltry actual invoice raised and paid but that was the reality.
Now benefit of the doubt and all that, they may have more jam tomorrow, sorry i mean pipeline, do forgive me but, will that convert to bottom line cash taken in invoices actually raised and paid into the business in the H2?
My call is despite a willingness not to want to raise again so soon, I don't see as they have an option. Unless something material fully paid up lands sharpish, a further raise to meet the current plan objectives looks inevitable to me now but WTFDIK just my opinion. A top up £3m raise at 0.50 or 0.40 would that be enough? extend the runway by 10 months to allow cash to actually land? Not sure
Be interesting how this unfolds short term anyhow, this play is not for widows or orphans that's for sure.
Probably hype but it looks a cheap buy in now imo and they are making progress and I'm very curious to see what happens with the Unilever collaboration.
Started: LTbeliever, 23 May 2024 07:19
Last post: LTbeliever, 23 May 2024 07:19
"Company anticipates further contracts, currently in final negotiation stages, will close before the financial year's end"
"Upon success in this project, there is potential for further downstream development contracts for Aptamer. "
"contracts in the pharmaceutical industry often take significant time to negotiate, frequently include confidentiality restrictions, and sometimes do not meet the materiality threshold for individual announcements."
"We continue to make good progress with our developed Optimer assets, with ongoing discussions around our drug delivery vehicles for the liver. Additionally, our work with Unilever developing Optimers in cosmetics applications continues to advance, alongside our partnership with Neuro-Bio to deliver Optimer binders for use in a rapid diagnostic test for Alzheimer's disease."
Started: bobbust, 22 May 2024 08:25
Last post: bobbust, 22 May 2024 08:25
The hangover from last raise still holding this back. An MC for a company like this of 40m would not be out of place.
Once the Spector of a further raise is gone this will rocket.
Every deal is pushing the need for a raise further away
Started: LTbeliever, 22 May 2024 07:11
Last post: Janiax, 22 May 2024 08:15
The news shows the company direction, and hints towards more growth coming.
This can be the start of the buy in rumour of a big recovery from a very large drop over the previous year.
People will want back in here before bigger news now.
It could see a very healthy blue day today and continue this week.
It could also generate some increase then have people dump again...
I'm hoping the continuation of blue days now so the reversal can start.
Good luck holders.
When the optimers have been developed I wonder what the terms of the licence will be ?
I don't expect a major sp rise on this news, but it is good news thou
Good to see they are making headway and I would expect to us positive today.
More excellent news. It would help to know over what period(s) £465k will be earned and booked. A few more new partnerships like this will really help investors not to fear another discounted equity fund raise, which is still holding the SP back after events of 2023.
Started: Bearsandbulls, 22 May 2024 08:02
Last post: Bearsandbulls, 22 May 2024 08:02
Is that spread real??
Gla
Started: LTbeliever, 21 May 2024 17:33
Last post: LTbeliever, 21 May 2024 17:33
Released on APTA's LinkedIn and site, y'day:
https://aptamergroup.com/new-paper-small-molecule-drug-monitoring-for-poc-tests/
" The paper represents an innovative approach in the field of drug monitoring. This work involved a significant partnership between the unit of experimental and clinical pharmacology of the National Cancer Institute and Aptamer Group, paving the way for future collaborations, underpinning the relationships between private businesses and public institutions. The use of aptamers to optimise drug dosage looks toward the horizon of personalised and tailored medicine, which is a new frontier in oncology." Lead Author Dr Giuseppe Toffoli
Started: LTbeliever, 21 May 2024 12:38
Last post: LTbeliever, 21 May 2024 12:38
FWIW, this is the growth plan to 2030; I assume APTA will be a partner in this journey (especially re Oncology);
"AstraZeneca set out its ambition to achieve USD80 billion in annual revenue by the end of the decade, as the pharmaceutical firm looks to bolster its oncology offering, its rare disease portfolio and launch 20 new treatments. The revenue target would represent a 75% jump from the USD45.81 billion it achieved in 2023. Chief Executive Officer Pascal Soriot said ahead of an investor day: "Today AstraZeneca announces a new era of growth. In 2023 we delivered the ambitious USD45 billion revenue goal set a decade ago. With the exciting growth of our innovative pipeline, which has the potential to transform millions of lives, we are now aiming for USD80 billion by 2030. We are planning to launch 20 new medicines by 2030, many with the potential to generate more than USD5 billion in peak year revenues. The breadth of our portfolio together with continued investment in innovation supports sustained growth well past the end of the decade."
Started: LTbeliever, 14 May 2024 18:54
Last post: LTbeliever, 14 May 2024 18:54
Https://www.turnerpope.com/wp-content/uploads/2024/05/Aptamer-Group-plc_28-3-2024_FINAL_BG.pdf
This is from March end (as for non-TP clients, it's released at least 1 month late) but still some useful comments, especially re CFlow:
"...Aptamer stated that in order to achieve a positive EBITDA and cash break even during the year ending 30 June 2025, it was targeting revenue of £3.0 million for current period rising to £6.0 million for the year ending 30 June 2026. While management prudently states that the first revenue target is likely to be missed, it nevertheless remains
possible to exceed this amount in the coming financial year, assuming the Group’s entire advanced pipeline will be
successfully converted along with delivery of all work-in-progress. Subject to change of course, the second revenue
target, along with ambition to achieve cash neutrality during FY2025/26, is now in place. .. this is not altogether unrealistic. Supporting such expectations, it is worth highlighting the extent of repeat business with large pharma partners, which presently includes work for a top 5 company to develop multiple Optimer® binders for different applications and no less than 18 separate contracts from two other top 15 partners. Elsewhere, the Group reports successful progression with Unilever for novel applications in FMCG, while entering a second phase of development with Neuro-Bio for Optimer® binders to enable Alzheimer’s disease lateral flow diagnostics. For the latter two, patent applications are currently being prepared."
..."transitioning of Neuro-Bio’s binders to a LFD development partner before the end of the calendar year";
"While the highly technical nature of such work means that lead times can often be relatively extended, continuing
to develop multiple new product opportunities within its rapidly emerging subsector of next generation affinity
ligands, for which APTA justifiably claims technological leadership, ensures a sticky and not particularly price
sensitive customer base. Breakthrough adoption of any of the Group’s patented novel applications by any of its
major partners could of course be transformative both financially (in terms of downstream licensing revenues) and
industrywide reputation."
Last post: LTbeliever, 14 May 2024 18:10
Mozax, don't know, it tried to break through 0.90 twice, maybe 3rd time lucky?
Arron sounded bullish in the RNS, for me it was "certainty" of more contracts tb signed by June end; if it does indeed happen, then yes, SP should return to +1p.
Won’t take much to set this alight, sellers have disappeared & it seems stock is tight.
Argyle, they bought in at 0.80...last week SP was 0.63...they paid a 27% premium to last week's SP, NOT a discount; and, most of us here ARE long term investors, hence our points about licensing revenues coming etc, which some others dismiss as "JAM tomorrow".
I have been posting since February that there will be no placing (mainly because there are revenues coming in regularly, at small sums adding up and thus not RNSed) and I have been adding small lots too.
Perhaps there’s a whiff of news regarding something ‘material’.
Cornerstone investors get 1st dibs at the best prices LT. Just means they see long term value at these prices and have the capital to risk.
Started: LTbeliever, 14 May 2024 07:15
Last post: LTbeliever, 14 May 2024 07:15
FROM THE FT ----https://www.ft.com/content/a7cb45a5-c2d7-4d7f-81f4-e4922d79b6c7-----
Is this good for Apta's (expected!) LTF tests? Or complementary to it? LTF helping diagnosis, vaccine treating it?
"Japan’s Takeda Pharmaceuticals has reached a deal worth up to $2.2bn to develop an Alzheimer’s vaccine made by Swiss start-up AC Immune, as drug companies race to invest in potentially lucrative new treatments for the disease. The vaccine is one of a wave of new drugs heading for the market, including lecanemab, developed by Japanese company Eisai, which received US regulatory approval last year. In the Takeda deal, AC Immune will receive an upfront payment of $100mn, rising to $2.1bn if milestones are reached, as well as more than 10 per cent in royalties from any worldwide sales. The Japanese group could advance the product to late-stage, phase 3 trials, AC Immune said, but regulatory approval could take several years. Early trials had identified no safety concerns, said Andrea Pfeifer, chief executive of the biotech. But AC Immune would not have efficacy data for the drug until it completed a mid-stage trial within the next 12 months..."
Started: NoOneKnows, 13 May 2024 08:05
Last post: LTbeliever, 13 May 2024 14:38
Talking about "pump", I forgot to mention UNILEVER too (revenues in a couple of years, plus fee-for service until we get there); :)))))
A good run of pump now is the order of the day before discounted placing.
Only a few weeks left now, either cash has actually come into the bank on paid orders or it hasn’t.
The figures need to do the talking now, nothing else counts.
They can talk, talk talk about how great the POTENTIAL is and the size of the dollop of JAM but if all your business drops off and nobody is paying you its going to be one hell of a hard sell for further investment. Results in H1 were absolutely shocking.
Lets see what comes in as fully paid up, if its derisory again, SH will need to dig deep to keep it going.
Just to add that the IPO-Mkt cap of 80mln was mainly predicated on these licensing deals' potential, rather than the fee-for service; as we know, the Co run out of cash in the meantime and the edifice came down; however, the potential is still there, we just had a delay in execution.
GLA
Thanks AR. IMO (rather biased!), there will be no Placing this year as the cash - at end of Jan - sufficed to Aug-Sept, WITH NO SALES/INCOME from thereon (which is highly unlikely, given the 4.5 mln pipeline and signed deals so far); also, at any time from today until the Autumn, there could potentially be a licensing deal (up to 6-8 mln were mentioned 3 months ago); although this would be for the medium term, the impact would fall straight to Profit (i.e. no WCapital needed), plus there would be profile-raising, more approaches for business etc, so I hope a Placing would no be needed; we know (announced) that licensing deals could be close with the Top 5 and 15 Pharmas, also with Neuro-bio for the LTFs (within 2024, was mentioned in the Interims Presentation), plus NOVAVX has a licensing potential; plus others we may not know about.
All IMO.
LT it pays to ignore any reference to pipeline or potential deals here and just concentrate on those signed, which still, as you rightly acknowledge, take a little time to convert to revenues.
As with all AIM/growing companies, they tend to emphasise positives rather than the harder realities (i.e. bank balance) which does sometimes make it harder to track where exactly things are financially.
We know from Arrons twitter chats that with the cash in hand and signed deals, they should have a runway until December with nothing new added.
Since February we only know that they've been working through their order book , but what the exact figures are only they know.
Everyone here knows the potential of APTA, it's just about the time taken/funds needed either raised or from trading in order to get there.
My guess (hope?) is that they will look to fundraise from a position of recently signed deal strength in the late summer/autumn.
Started: missilee, 13 May 2024 09:04
Last post: missilee, 13 May 2024 09:04
Aptamer remains firmly focussed on the first of these three objectives and is pleased to report progress on the second two objectives.
Since the announcement of the half year results, the Group has made significant progress in regarding its new platform technology, Optimer®+, through an initial soft launch and agreement of the first commercial sale.
Patents have been filed to protect the Optimer binders developed in partnership with Unilever for use in cosmetics applications to support ongoing commercial discussions between the two companies, with further testing underway. A follow-on deal has been signed with Neuro-Bio to develop a second Optimer binder to enable a wholly Optimer-powered lateral flow test for the early detection of Alzheimer's disease. Furthermore, the Group has made significant progress in the precision gene therapy space, demonstrating Optimer performance in lab-based tests as drug delivery vehicles specific to the cells associated with fibrotic liver disease and establishing chemical manufacturing methods for scaled test batches. These Optimer-conjugates are currently undergoing evaluation by a top 15 pharma partner, with additional negotiations underway with a major top 10 pharmaceutical company to explore the Optimer-conjugates as part of a proof-of-concept study.
The Group's current sales pipeline is strong, with over £3.0 million in advanced stage discussions. A proportion of these advanced stage deal negotiations is anticipated to progress through the laboratory before the end of the financial year. This anticipated deal value is in addition to the c.£1.4m of existing signed deals already at various stages of completion in the production laboratory. Revenue recognition on all signed deals is further subject to the receipt of target material in a timely manner from customers, and scientific attrition.